Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
Status:
Active, not recruiting
Trial end date:
2040-12-31
Target enrollment:
Participant gender:
Summary
Three parallel cohort, multicenter, open-label, phase I/II clinical trial to analyze the
safety and feasibility of PD-1 inhibition with Nivolumab given concomitantly with standard
radiotherapy regimens in the treatment of esophageal cancer